Literature DB >> 3141169

Comparative in vitro activity of cefpiramide, a new parenteral cephalosporin.

C Quentin1, P Noury, M Titonel.   

Abstract

The in vitro activity of cefpiramide was compared with that of nine other cephalosporins by determining the MIC values by means of an agar dilution method for 300 representative clinical isolates of nonfastidious bacteria. Cefpiramide had a broad-spectrum of activity, similar to that of the third-generation cephalosporins. As judged by the MIC50 and the MIC90 values, cefpiramide was one of the most active cephalosporins against Pseudomonas aeruginosa (MIC50 2.9 micrograms/ml, MIC90 64 micrograms/ml), staphylococci (MIC50 1.2 micrograms/ml, MIC90 10 micrograms/ml) and Enterococcus faecalis (MIC50 13 micrograms/ml, MIC90 43 micrograms/ml). Cefpiramide had moderate activity against Enterobacteriaceae (MIC50 4 micrograms/ml, MIC90 108 micrograms/ml), comparable to that of the older second-generation cephalosporins. Ticarcillin-resistant strains of gram-negative rods were inhibited by higher concentrations of cefpiramide than ticarcillin-susceptible strains.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141169     DOI: 10.1007/bf01962612

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity.

Authors:  M Fukasawa; H Noguchi; T Okuda; T Komatsu; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

2.  Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.

Authors:  H Matsui; K Yano; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

3.  In vitro antibacterial activity of cefpiramide.

Authors:  M A Pfaller; A C Niles; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Pharmacokinetics of cefpiramide (SM-1652) in humans.

Authors:  K Nakagawa; M Koyama; H Matsui; C Ikeda; K Yano; N Nakatsuru; K Yoshinaga; T Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria.

Authors:  H Wexler; W T Carter; B Harris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

6.  Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

Authors:  M Kato; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

7.  Cefpiramide: comparative in-vitro activity and beta-lactamase stability.

Authors:  A L Barry; R N Jones; C Thornsberry; P C Fuchs; L W Ayers; T L Gavan; E H Gerlach; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

8.  Comparative in vitro activities of cefpiramide and apalcillin individually and in combination.

Authors:  J D Allan; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

  8 in total
  1 in total

1.  Cefpiramide kinetics and plasma protein binding in cholestasis.

Authors:  F Demontes-Mainard; G Vinçon; L Labat; M Amouretti; J Necciari; G Kieffer; B Bannwarth
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.